For research use only
| Cat No. | ABC-X0348C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Host Cell | MC38 |
| Source Organ | Colon |
| Disease | Colon Adenocarcinoma |
| Storage | Liquid Nitrogen |
Human PD1 (LAG3) MC38 Cell Line, PD1, MC38, Overexpression Stable Cell Lines, Transfected Stable Cell Lines
Human PD1 (LAG3) MC38 Overexpression Cell Line is a genetically engineered model derived from murine MC38 colon adenocarcinoma cells based on customers’ requirement. PD1 (LAG3) MC38 overexpression cell line stably expresses human PD1 and LAG3 immune checkpoint proteins via lentiviral delivery. The dual-expressing clone is validated by qRT-PCR and maintained at low passage numbers (<P20). Target PD1 (PDCD1) and LAG3 are co-inhibitory receptors expressed on T cells and other immune subsets. Co-expression of these targets in tumor models allows the study of immune evasion and therapeutic response to checkpoint blockade. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0348C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Colon |
| Disease | Colon Adenocarcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | MC38 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model co-expresses human PD-1 and LAG-3 in the murine MC38 colorectal cancer cell line, enabling the study of immune checkpoint biology in a tumor microenvironment context. It is ideal for investigating immune evasion, evaluating anti-PD-1 and anti-LAG-3 antibodies, and modeling dual-checkpoint blockade strategies. The cell line is widely applied in immuno-oncology research and syngeneic mouse model development for preclinical therapeutic testing.